- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Infusions of amsacrine
Leukaemia - acute
For the induction and maintenance of remission in acute leukaemia of adults.
Effective in patients refractory to anthracycline monotherapy or in combination, and in patients who were formerly treated with maximum cumulative doses of anthracyclines.
Induction of remission phase:
The recommended dose is 90 mg/square metre body surface area every day for 5 consecutive days (total dose 450 mg/square metre). The course may be extended for an additional 3 days if a bone marrow biopsy performed on day 6 displays over 50% cellularity and the blast count is over 30%.
Subsequent courses are given at 2 to 4 week intervals depending on the effectiveness of first cycle at producing myelosuppression. If a hypocellular marrow has not been achieved after the first course, the daily dose may be increased to 120 mg/square metre, provided this is not contraindicated by non-myelosuppressive toxicity.
Maintenance dose is approximately one third of the total induction dose, (i.e. 150 mg/square metre) given either as a single intravenous infusion or divided (i.e. of 50 mg/square metre per day) over 3 consecutive days.
This should be repeated every 3 to 4 weeks.
Each maintenance course should bring the granulocyte count to 1,000 to 1,500 per microlitre and the platelet count to 50,000 to 100,000 per microlitre. If this is not achieved, the maintenance dose may be increased by 20% every second course. The granulocyte and platelet counts should be allowed to recover between the courses to over 1,500 per microlitre and 100,000 per microlitre respectively.
The leucopenia nadir usually occurs after 5 to 12 days, with recovery usually following by the 25th day.
Patients with Renal Impairment
Decrease the dose by 20 to 30% (to 60 to 75 mg/square metre) in patients with GFR below 50 ml/minute.
Patients with Hepatic Impairment
Decrease the dose by 20 to 30% (to 60 to 75 mg/square metre) in patients with hepatic impairment.
For intravenous infusion (after dilution)
Children under 12 years
Myelosuppression secondary to chemotherapy
Myelosuppression secondary to radiotherapy
Precautions and Warnings
Reduce dose in patients with hepatic impairment
Reduce dose in patients with renal impairment
Consider premedication with hypouricaemic agent
Treatment to be initiated and supervised by a specialist
Accidental contact of soln with skin/mucous membranes-rinse well with water
Consult local policy on the safe use of anti-cancer drugs
If extravasation occurs follow local policy & seek expert help immediately
Incompatible with plastic
Staff: Not to be handled by pregnant staff
Correct serum potassium levels before commencing treatment
Monitor serum electrolytes before and during treatment
Monitor cardiac function
Monitor hepatic function
Monitor patients for signs of tumour lysis syndrome
Monitor renal function
Monitor uric acid levels
Perform regular white blood cell and platelet counts
May cause tissue irritation
Suspend / reduce dose if excessive drop in WBC / bone marrow occurs
Suspend treatment if granulocyte count is less than 1500 per cubic mm
Suspend treatment if platelet count is less than 100,000 per cubic mm
May cause impaired fertility
Female: Contraception required during and for 3 months after treatment
Male: Contraception required during and for 6 months after treatment
Complete blood counts should be performed frequently as the drug may cause severe bone marrow depression. If an exceedingly large fall in white cell count and excessive depression of bone marrow occurs it may be necessary to suspend treatment or reduce dose. Appropriate transfusions should be available.
Pregnancy and Lactation
Amsacrine is contraindicated during pregnancy.
The manufacturer discourages the use of amsacrine during pregnancy, especially during the first trimester. There are no data on the use of amsacrine in pregnant women, however, animal studies have indicated that amsacrine is teratogenic and has shown reproductive toxicity.
Amsacrine is contraindicated during breastfeeding.
The manufacturer recommends that breastfeeding is contraindicated during amsacrine treatment. It is unclear whether amsacrine is excreted in the mother's milk.
Acute renal insufficiency
Blood urea increased
Congestive cardiac failure
Decreased ejection fraction
Grand mal seizure
Increase in alkaline phosphatase
Increases in hepatic enzymes
Irritation (injection site)
Lability of affect
Necrosis (injection site)
Phlebitis (injection site)
Serum bilirubin increased
Serum creatinine increased
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: August 2022
Summary of Product Characteristics: Amsidine 75mg/1.5ml concentrate and solvent for solution for infusion. Eurocept International BV. Revised March 2020.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.